DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM 538 MG / 100 ML — DIN 00865095
SODIUM CHLORIDE : 538 MG / 100 ML CALCIUM CHLORIDE : 18.3 MG / 100 ML DEXTROSE : 1.5 G / 100 ML SODIUM LACTATE : 448 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML · VANTIVE ULC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM?
DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM 538 MG / 100 ML contains SODIUM CHLORIDE : 538 MG / 100 ML CALCIUM CHLORIDE : 18.3 MG / 100 ML DEXTROSE : 1.5 G / 100 ML SODIUM LACTATE : 448 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00865095, held by VANTIVE ULC, supplied as SOLUTION for HAEMODIALYSIS (INTRAPERITONEAL) administration. Health Canada currently lists it as marketed, status dated 12-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM used for?
Acute or chronic renal failure; certain fluid and electrolyte disturbances; intoxication with certain poisons and drugs.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Hemodialytics, Concentrates in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
22 holders have a Canadian DIN containing Hemodialytics, Concentrates, across 588 DINs, of which 117 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| VANTIVE ULC | 57 | 52 | ACID CONCENTRATE 2156, ACID CONCENTRATE 2182, ACID CONCENTRATE D12201, ACID CONCENTRATE D12207, ACID CONCENTRATE D12236, +51 more | Sourceable in Canada |
| CHIEF MEDICAL SUPPLIES LTD | 99 | 39 | ACID CONCENTRATE A1220, ACID CONCENTRATE A1221, ACID CONCENTRATE A1222, ACID CONCENTRATE A1223, ACID CONCENTRATE A1224, +75 more | Sourceable in Canada |
| FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP, LLC | 34 | 18 | NATURALYTE H-200, NATURALYTE H-201, NATURALYTE H-206, NATURALYTE H-208, NATURALYTE H-225, +29 more | Sourceable in Canada |
| NXSTAGE MEDICAL INC | 8 | 6 | NXSTAGE PUREFLOW DIALYSATE CONCENTRATE (SAK 303), NXSTAGE PUREFLOW DIALYSATE CONCENTRATE (SAK 304), NXSTAGE PUREFLOW DIALYSATE CONCENTRATE (SAK 305), NXSTAGE PUREFLOW DIALYSATE CONCENTRATE (SAK-301), NXSTAGE PUREFLOW DIALYSATE CONCENTRATE (SAK-302), +3 more | Sourceable in Canada |
| FRESENIUS MEDICAL CARE CANADA INC | 12 | 2 | BIBAG, DELFLEX PERITONEAL DIALYSIS SOLUTION WITH 0.5% DEXTROSE, NATURALYTE H-202, NATURALYTE H-223, NATURALYTE H-224, +6 more | Sourceable in Canada |
| BAXTER CORPORATION | 108 | 0 | 800 SODIUM BICARBONATE POWDER, ACID CONCENTRATE 2100, ACID CONCENTRATE 2101, ACID CONCENTRATE 2102, ACID CONCENTRATE 2105, +95 more | No marketed DIN |
| GENPHARM ULC | 89 | 0 | ACID CONCENTRATE (R04146), ACID CONCENTRATE (R04938), ACID CONCENTRATE (R04968), ACID CONCENTRATE (R04969), ACID CONCENTRATE (R04974), +79 more | No marketed DIN |
| HAEMOTEC, A DIVISION OF FRESENIUS MEDICAL CARE CANADA INC. | 53 | 0 | CALCIUM CHLORIDE ADDITIVE 0.13-4.5L, H-629, H-700, H-701, H-702, +48 more | No marketed DIN |
| ALTHIN BIOPHARM INC. | 43 | 0 | ACID CONCENTRATE 2109, ACID CONCENTRATE 2165, ACID CONCENTRATE 2166, ACID CONCENTRATE 2168, ACID CONCENTRATE 2187, +38 more | No marketed DIN |
| BDH INC. | 22 | 0 | ACETATE CONCENTRATE R07318 LIQ, ACETATE CONCENTRATE R07376, ACID CONCENTRATE RX252C, ACID CONCENTRATE RX253C, ACID CONCENTRATE-R04948 LIQ, +17 more | No marketed DIN |
| BICARBOLYTE CORPORATION | 15 | 0 | BICARB HEMODIAL CONC 36.83, BICARB HEMODIAL CONC 36.83X ACID, BICARB HEMODIAL CONC 81.25GM/L, BICARBOLYTE BICAR HEMODIALSIS CONC, BICARBOLYTE BICAR HEMODIALYSIS CONC, +1 more | No marketed DIN |
| RENAL SYSTEMS, DIVISION OF MINNTECH CORP. | 15 | 0 | ACID HEMODIALYSIS CONC SB 1003, BC-I CONCENTRATE PWR, BICARBONATE CONC MB-330 PWR 650MG/PCK, RS-274, SB 1000, +10 more | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 538 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | HAEMODIALYSIS (INTRAPERITONEAL) |
| Pack configuration (monograph) | Viaflex plastic containers in nominal sizes: 1500 mL, 2000 mL, 2500 mL, 3000 mL, and 5000 mL. |
| Storage | Store at 15°C to 25°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Hemodialytics, Concentrates |
|---|---|
| ATC code | B05ZA |
| AHFS class | 40:34.00* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00865095 |
|---|---|
| DIN (unpadded, as printed on some documents) | 865095 |
| Brand name | DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM |
| Generic / active ingredient | SODIUM CHLORIDE : 538 MG / 100 ML CALCIUM CHLORIDE : 18.3 MG / 100 ML DEXTROSE : 1.5 G / 100 ML SODIUM LACTATE : 448 MG / 100 ML MAGNESIUM CHLORIDE : 5.08 MG / 100 ML |
| Market authorization holder | VANTIVE ULC |
| Health Canada schedule | Ethical |
| ATC code | B05ZA |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05ZA |
| Current status | MARKETED |
| Status date | 12-Apr-2024 |
| Original market date | 1990-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Intraperitoneal only. Mode (IPD, CAPD, APD), volume, and frequency determined by physician. Warm to 37°C using dry heat only. Aseptic technique required. Single use only.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Severe lactic acidosis; uncorrectable mechanical defects preventing effective dialysis; documented loss of peritoneal function or extensive adhesions.
Warnings and precautions
Risk of Encapsulating Peritoneal Sclerosis (EPS); corn allergy caution; monitor for lactic acidosis, electrolyte imbalances, and fluid balance; not for intravenous use.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
117 of 588 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | 02533774 |
2 · Same class — other molecules in ATC B05ZA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Hemodialytics, Concentrates | 800 SODIUM BICARBONATE POWDER · ACETATE CONCENTRATE R07318 LIQ · ACETATE CONCENTRATE R07376 · ACID CONCENTRATE (R04146) · +538 more | 588 | 117 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05Z
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05ZB | Hemofiltrates | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for DIANEAL PD4 CAPD SOLUTION WITH 1.5% DEXTROSE AND 2.5MEQ/L CALCIUM
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.